BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27159396)

  • 1. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.
    Lock R; Ingraham R; Maertens O; Miller AL; Weledji N; Legius E; Konicek BM; Yan SC; Graff JR; Cichowski K
    J Clin Invest; 2016 Jun; 126(6):2181-90. PubMed ID: 27159396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
    Malone CF; Fromm JA; Maertens O; DeRaedt T; Ingraham R; Cichowski K
    Cancer Discov; 2014 Sep; 4(9):1062-73. PubMed ID: 24913553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.
    Grit JL; Pridgeon MG; Essenburg CJ; Wolfrum E; Madaj ZB; Turner L; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32245042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Calizo A; Pratilas CA
    Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
    Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
    Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
    Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
    Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
    Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
    Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
    Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
    Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
    Grit JL; McGee LE; Tovar EA; Essenburg CJ; Wolfrum E; Beddows I; Williams K; Sheridan RTC; Schipper JL; Adams M; Arumugam M; Vander Woude T; Gurunathan S; Field JM; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
    Oncogene; 2024 May; 43(19):1411-1430. PubMed ID: 38480916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
    Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
    Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.